MedTrace Logo

NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer

NCT02425072 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-08-10

No results posted yet for this study

Summary

The hypothesis of this study is that the addition of NovoTTF-100A System treatment to salvage chemotherapy will significantly increase time to treatment failure in the brain of small cell lung cancer patients.

Conditions

Interventions

DEVICE

NovoTTF-100A plus chemotherapy

NovoTTF-100A System with Physician's Choice Chemotherapy

Sponsors & Collaborators

  • John Villano

    lead OTHER

Principal Investigators

  • John L Villano, MD, PhD · Lucille P. Markey Cancer Center at University of Kentucky

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2021-07-31
Completion
2022-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02425072 on ClinicalTrials.gov